The one thing that does worry me about 'patient involveent', is that many many utterly crap and harmful studies have been done with 'patient involvement'. PACE with AfME, all Crawley's stiudies with patient support from her clinics, the Sussex org (whatever thats called). So the problem is this:
Which patients.
It's a risk of course, that the 'wrong' patients end up in decision-making roles. But I think it's a risk that has to be accepted. I think the key is education of people with ME/CFS. I don't think AfME or any major UK ME/CFS charity would allow another PACE. It's important that we get people with ME/CFS on the boards of charities, as they do a lot of the educating of patients, the selection of staff and the choosing of research to support. And I think there has to be accountability. Patients in decision-making roles should be willing to be named.
One way to resolve this could be requiring the endorsement of X charter-signing organizations, rather than just one. Depends on how many there are in total. Not too onerous, but enough to make it sure that it isn't some fringe issue. The process of endorsement shouldn't be onerous either, it should be simple and charter-signing organizations should be prepared to give a quick assessment.
I think we have to keep in mind that any requirements have to be proportionate. Someone doing a short thesis for their Masters degree should not have to get multiple patient organisations to give their approval.
If the goal is to ensure the scientific integrity and standard, that is really the job of scientific community, not patients.
Others have addressed this, but, no. It's a bit like saying that the goal of democracy is only the job of politicians. Absolutely, the people affected by the science should have a role in deciding who gets funds, and they have a role in setting the standards that should be followed and in holding researchers to account. It's true in any field - AI, genetic modification... - the ideal is an engaged society that helps to ensure scientists deliver benefits, not harm.
No reference to "deficit thinking", etc., in other words.
Yeah, that's an interesting one and I wondered if there would be push-back on that. I had the same reaction when I first came across the term, and it is still a bit challenging, it does feel rather 'woke' or 'wet'. But, it's been used a lot where I live, in relation to research about people of various ethnicities. And I think it does have value in countering entrenched prejudice. Maybe have a read of some of the literature about it
@poetinsf. And, think about that study I mentioned upthread, the one that found no differences in a handful of molecules in the blood that we already knew weren't different, and then managed to leap to suggesting that this indicated psychosomaticism. And the effort preference conclusion from a barely significant result of an incredibly poorly conceived and executed test. And the readiness of researchers to label us as hysterical and catastrophising when we disagree with their research. A lot of the CFS research we see is approached with enormous prejudice and with the conclusions written before the results come in.
The phrase 'deficit thinking' is one that I'd be willing to let go, I know it can cause eye-rolling. I know it's a bit tricky to apply to a disease community too - because clearly there is some problem within us that we want to fix. But, 'deficit thinking' is an idea that is gaining ground, and the fierceness with which, for example, Māori communities are challenging prejudice is a bit inspiring. I think it can be a useful label to put on ideas of 'if you thought differently, behaved differently, there would be no problem, the problem is you and you need to fix yourself, so stop complaining', whether that be at the individual health level or the societal level.
And I don't think inserting patient groups in every stage of the study will fly. (It immediately conjures up USDA inspection process for meat packing.) Even then, it will still look "beyond bizarre", to borrow Sean's words, for patients to set the standards.
I don't think that is what anyone is suggesting, for every study. Again, the Masters student doing a project might just have a panel of three people with ME/CFS as their advisory group, or they might chat with the local patient group at the beginning and at the end of their study. For something as ethically and logistically challenging as DecodeME (requiring a huge number of participants to donate extremely personal information), it does make sense to have patients fully integrated into the study. I think the complexities could be covered by a simple statement along the lines of 'there is involvement of people with ME/CFS proportionate to the size and ethical complexity of the study'. Then a bit of discussion about what that might look like for different sorts of studies.
I envisage this Charter as something quite general that biobanks, patient charities, funding organisations and research institutes could all sign up to. And it's not about guaranteeing perfection, but just indicating a movement towards it.
In what other disease do we have this? The shoddy practices that you mentioned is not limited to ME/CFS research. If it weren't for BPS, and how we feel misunderstood by the BPS champions, would we even have the need for this action?
So, should all patient groups now have Charter for the researchers? Whatever is going on in the scientific community can't be unique to ME/CFS. But ME/CFS community feel the need for action because ME/CFS patients are particularly misunderstood. Saying that we are taking action because of shoddy scientific practices is not too convincing.
Absolutely the problems are not limited to ME/CFS or to BPS research. National ethical guidelines and the deliberations of ethics committees should be producing better outcomes. But they aren't, certainly not in every country all the time. We can work on changing that, but, in the meantime, we could start trialling these ideas. Other communities are working on the problems too.
On the idea of banning research with subjective outcomes and a lack of blinding, I wouldn't want to do that. Fluge and Mella reported on trials like that - they didn't pan out, but it was a reasonable part of the process of doing science. The important point was that they didn't draw any definitive conclusions from those studies, they knew that they needed to proceed on with Phase 3 trials if they wanted to conclude that a treatment helped. So, I think the requirement might be more around a commitment to not make, or publicise, conclusions that go beyond what the data suggests - and then give some examples in the discussion. So, that could stop the conclusion of psychosomaticism on the basis of CRP and IL-6 not being different and the conclusion that GET or a drug cures ME/CFS on the basis of a short term study with only subjective outcomes.